Affordable Access

Publisher Website

Thrombolytic Treatment of Acute Ischemic Stroke

Authors
Journal
Mayo Clinic Proceedings
0025-6196
Publisher
Elsevier
Publication Date
Volume
77
Issue
6
Identifiers
DOI: 10.4065/77.6.542
Disciplines
  • Communication
  • Medicine

Abstract

Intravenous recombinant tissue-type plasminogen activator is approved by the US Food and Drug Administration for treating acute ischemic stroke within 3 hours of onset of symptoms. Initiation of thrombolysis within 90 minutes of onset of symptoms is a treatment goal supported by current studies. Postmarketing data suggest that the risk of intracranial hemorrhage may be unacceptably high when recombinant tissue-type plasminogen activator is given to patients who would not have been eligible for enrollment in the pivotal phase 3 clinical trials. Further studies of local intra-arterial thrombolysis and improved selection of patients with advanced brain imaging are expected in the future, but the emphasis at present should be on rapid identification, evaluation, and treatment of appropriate patients with intravenous therapy.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Thrombolytic treatment of acute ischemic stroke.

on Mayo Clinic Proceedings June 2002

[Thrombolytic treatment of acute ischemic stroke].

on Revista clínica española June 2007

New insights on thrombolytic treatment of acute is...

on Current Neurology and Neurosci... January 2001

Thrombolytic treatment after acute ischemic stroke...

on Journal of vascular and interv... January 2009
More articles like this..